Provider matchup · September 2026
bmiMD vs Direct Meds
Both sell sermorelin and nothing else, but bmiMD adds a sublingual format and publishes 50-state coverage, while Direct Meds holds one monthly figure across two supply lengths.
Full reviews: bmiMD and Direct Meds. Both sell 1 compound this site boards: Sermorelin.
At a glance
| Dimension | bmiMD | Direct Meds |
|---|---|---|
| Compounds offered | Sermorelin only. No other peptide appears on the menu. | Sermorelin only. No other peptide appears on the menu. |
| Delivery formats | Two: a daily injection and a sublingual tablet. | One: an injection, sold as a 30-day or a 90-day supply. |
| Compounds with a checked price | Sermorelin, with a separate rate published for each of the two formats. | Sermorelin, with one figure covering both supply lengths. |
| Pricing structure | The injectable rate is monthly with no commitment. The sublingual rate is lower per month but billed quarterly, so the first charge covers three months. | A flat monthly figure that does not change whether the order is billed as a 30-day or a 90-day supply. |
| States published | All 50 states. | No full state list is published. Mississippi, Louisiana and California are named as excluded. |
| Operating company named | Yes. Medccm Inc. | A Utah telehealth company. Its previously named 503A pharmacy partners were removed from public view. |
| Pharmacy named | No. The facility that compounds the prescription is not identified. | No, as of a mid-July 2026 site check. Generic licensed-compounding-pharmacy wording replaced the earlier named partners. |
| Public record to read | A public Trustpilot profile the company points to. | A September 2025 FDA warning letter about GLP-1 marketing claims, and a BBB profile averaging 1.12 out of 5 across 226 reviews. |
The short answer
Both companies sell sermorelin and nothing else in the peptide category, so this is a comparison of terms rather than of menus.
bmiMD offers a choice of format and publishes coverage in all 50 states. Direct Meds offers one format and holds a single monthly figure whether a buyer takes a 30-day or a 90-day supply.
Direct Meds also carries a September 2025 FDA warning letter and a poor BBB review record, both of which are covered below. Neither one settles the choice on its own.
One compound, two ways to take it
bmiMD sells sermorelin as a daily injection and as a sublingual tablet. A tablet route is uncommon in a category that defaults to vials and syringes.
That choice matters more than it sounds. Needle aversion ends plenty of peptide programs in the first month, and a second format removes that failure point.
Direct Meds sells sermorelin as an injection only. Its flexibility sits in the billing term rather than in the route.
How each one prices the month
Direct Meds charges the same monthly figure whether the order is billed as a 30-day or a 90-day supply. A buyer who wants fewer reorder cycles pays no premium for the convenience, and a buyer who wants to stay flexible pays no penalty.
bmiMD prices its two formats differently. The injectable rate is quoted monthly with no commitment. The sublingual rate is lower per month, but it is billed quarterly, so the first charge covers three months at once.
The attractive number and the flexible number are not the same number at bmiMD, and the site leads with the attractive one. Compare the amount charged on day one, not the two per-month figures side by side.
The FDA warning letter Direct Meds received
Direct Meds received an FDA warning letter in September 2025. It concerned how the company marketed compounded GLP-1 drugs, presenting them as equivalent to the FDA-approved products.
The letter addresses marketing and labeling claims, which is what the large majority of warning letters address. It is not a finding about the contents of a vial, and it is not evidence that any medication was contaminated or ineffective.
It also does not concern the sermorelin line these two companies are being compared on. Direct Meds discloses the injectable and sublingual formats of the GLP-1 line named in the letter alongside it.
A letter discloses. It is here so a buyer can read it and weigh it, not because it decides anything.
The customer record, which is the sharper signal
BBB customer reviews of Direct Meds average 1.12 out of 5 across 226 reviews. Many of those accounts describe unexpected multi-month charges.
That points at billing rather than at product, and it is the more concrete concern of the two on the Direct Meds side. Read the subscription and cancellation terms closely before entering a card.
bmiMD points to a public Trustpilot profile instead, so its service claims can be read against customer accounts rather than taken on trust.
Where each one ships, and what neither names
bmiMD operates in all 50 states, so eligibility is settled before intake.
Direct Meds is not available in Mississippi, Louisiana or California, and it does not publish the full list of states it does serve. Buyers elsewhere have to confirm coverage during intake.
Neither company names the pharmacy that compounds a sermorelin prescription. Direct Meds once named its 503A partners publicly and, as of a mid-July 2026 check, had replaced those names with generic wording. A disclosure that narrows over time is worth more attention than one that was never made.
bmiMD does name the company behind the brand, Medccm Inc. Naming the legal entity is a real disclosure, and it is not the same as naming the facility.
Who each one suits
bmiMD
- Anyone who would rather take sermorelin as a sublingual tablet than a daily injection.
- Buyers who need coverage confirmed before intake, since all 50 states are published.
- Shoppers who want a public review profile and a named operating company to read first.
Direct Meds
- Buyers who want a sermorelin rate that holds steady across a 30-day and a 90-day supply.
- People who prefer fewer reorder cycles without paying more per month for the longer supply.
- Shoppers willing to read a warning letter and a customer-review record and weigh both themselves.
Frequently asked questions
What was the Direct Meds FDA warning letter about?
It was issued in September 2025 over how Direct Meds marketed compounded GLP-1 drugs, presenting them as equivalent to the FDA-approved products. It addresses marketing and labeling claims, which is what most warning letters address. It is not a finding about the contents of a vial, and it does not concern the sermorelin line compared here.
Should that letter rule Direct Meds out?
That is a decision for the buyer, and it should be an informed one. A warning letter tells you how a company promoted a product, not whether a medication was contaminated or ineffective. Read the letter, then weigh it against the BBB billing complaints, which describe a more concrete and more recent problem.
Do either of them sell peptides besides sermorelin?
No. Sermorelin is the entire peptide menu at both companies. Neither lists NAD+, glutathione, GHK-Cu, tesamorelin, BPC-157 or MOTS-C, so a shopper comparing several compounds at once needs a broader seller.
Which one is cheaper per month?
The figures are not comparable on their own, because the terms attached to them differ. The lower bmiMD rate covers the sublingual tablet under quarterly billing, so the first charge covers three months. Its injectable rate is monthly with no commitment. Direct Meds charges one figure across both of its supply lengths. Compare the amount charged on day one.
Can I order from any state?
With bmiMD, yes, since it operates in all 50 states. Direct Meds excludes Mississippi, Louisiana and California, and it does not publish the full list of states it serves, so buyers elsewhere should confirm eligibility during intake before paying.
Does either name the compounding pharmacy?
Neither one does today. bmiMD names its operating company, Medccm Inc., but not the facility that fills a prescription. Direct Meds once named its 503A pharmacy partners and, as of a mid-July 2026 check, had replaced those names with generic wording. Ask for the facility name during intake if it matters to you.